Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway

References

• GrossTJ, HunninghakeGW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517–525. doi:10.1056/NEJMra003200.11519507
   PubMed Web of Science ®Google Scholar
• FlahertyKR, ColbyTV, TravisWD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410–1415. doi:10.1164/rccm.200204-373OC.12615630
   PubMed Web of Science ®Google Scholar
• KolosovaI, NetheryD, KernJA. Role of Smad2/3 and p38 MAP kinase in TGF-beta1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol. 2011;226:1248–1254. doi:10.1002/jcp.22448.20945383
   PubMed Web of Science ®Google Scholar
• KasaiH, AllenJT, MasonRM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56. doi:10.1186/1465-9921-6-56.15946381
   PubMed Web of Science ®Google Scholar
• ChapmanHA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 2011;73:413–435. doi:10.1146/annurev-physiol-012110-142225.21054168
   PubMed Web of Science ®Google Scholar
• XiY, TanK, BrumwellAN, et al. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014;50:51–60. doi:10.1165/rcmb.2013-0099OC.23944988
   PubMed Web of Science ®Google Scholar
• YamadaH, TajimaS, NishikawaT. Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture. J Dermatol Sci. 1995;9:45–47. doi:10.1016/0923-1811(94)00355-i.7537081
   PubMed Web of Science ®Google Scholar
• SuzukiH, TanakaK, KaneshigeH, et al. The effects of long term Tranilast administration on bronchial hypersensitivity in asthmatics. Panminerva Med. 1989;31:88–93.2477786
   PubMed Web of Science ®Google Scholar
• QiW, ChenX, TwiggS, et al. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int. 2006;69:989–995. doi:10.1038/sj.ki.5000189.16528248
   PubMed Web of Science ®Google Scholar
• BetgeS, KunzC, FigullaH, et al. Late onset oral treatment with tranilast following large myocardial infarction has no beneficial effects on cardiac remodeling and mortality in rats. Exp Ther Med. 2014;8:1789–1796. doi:10.3892/etm.2014.2003.25371734
   PubMed Web of Science ®Google Scholar
• KaneyamaT, KobayashiS, AoyagiD, et al. Tranilast modulates fibrosis, epithelial-mesenchymal transition and peritubular capillary injury in unilateral ureteral obstruction rats. Pathology. 2010;42:564–573. doi:10.3109/00313025.2010.508784.20854076
   PubMed Web of Science ®Google Scholar
• TakahashiE, NaganoO, IshimotoT, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 2010;285:4060–4073. doi:10.1074/jbc.M109.056523.19965872
   PubMed Web of Science ®Google Scholar
• OkuH, ShimizuT, KawabataT, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590:400–408. doi:10.1016/j.ejphar.2008.06.046.18598692
   PubMed Web of Science ®Google Scholar
• EnomotoN, SudaT, KatoM, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006;130:22–29. doi:10.1016/j.ejphar.2008.06.046.16840378
   PubMed Web of Science ®Google Scholar
• AshcroftT, SimpsonJM, TimbrellV. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467–470. doi:10.1136/jcp.41.4.467.3366935
   PubMed Web of Science ®Google Scholar
• TakahashiF, TakahashiK, OkazakiT, et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001;24:264–271. doi:10.1165/ajrcmb.24.3.4293.11245625
   PubMed Web of Science ®Google Scholar
• HaradaT, WatanabeK, NabeshimaK, et al. Prognostic significance of fibroblastic foci in usual interstitial pneumonia and non-specific interstitial pneumonia. Respirology. 2013;18:278–283. doi:10.1111/j.1440-1843.2012.02272.x.23016880
   PubMed Web of Science ®Google Scholar
• LomasNJ, WattsKL, AkramKM, et al. Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers. Int J Clin Exp Pathol. 2012;5:58–71.22295148
   PubMed Web of Science ®Google Scholar
• ChristineLC, RobertAW. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi:10.1126/science.1203543.21436443
   PubMed Web of Science ®Google Scholar
• KevinKK, MatthiasCK, PaulJW, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103:13180–13185. doi:10.1073/pnas.0605669103.16924102
   PubMed Web of Science ®Google Scholar
• YamaguchiM, HiraiS, TanakaY, et al. Fibroblastic foci, covered with alveolar epithelia exhibiting epithelial-mesenchymal transition, destroy alveolar septa by disrupting blood flow in idiopathic pulmonary fibrosis. Lab Invest. 2017;97:232–242. doi:10.1038/labinvest.2016.135.27941755
   PubMed Web of Science ®Google Scholar
• JasonRR, ChristinaEB, MichaelJC, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(52):E1475–83. doi:10.1073/pnas.111798810822123957
   PubMed Web of Science ®Google Scholar
• SaltonF, VolpeMC, ConfalonieriM. Epithelial⁻mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis. Medicina (Kaunas). 2019;55:83. doi:10.3390/medicina55040083
   PubMed Web of Science ®Google Scholar
• SgallaG, IoveneB, CalvelloM, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19:32. doi:10.1186/s12931-018-0730-2.29471816
   PubMed Web of Science ®Google Scholar
• QianW, CaiX, QianQ, et al. Astragaloside IV modulates TGF -β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J Cell Mol Med. 2018;22:4354–4365. doi:10.1111/jcmm.1372529971947
   PubMed Web of Science ®Google Scholar
• KanemaruR, TakahashiF, KatoM, et al. Dasatinib suppresses TGFβ-mediated epithelial-mesenchymal transition in alveolar epithelial cells and inhibits pulmonary fibrosis. Lung. 2018;196:531–541. doi:10.1007/s00408-018-0134-629926178
   PubMed Web of Science ®Google Scholar
• IharaH, MitsuishiY, KatoM, et al. Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-β/Smad pathway. Respir Investig. 2020;58:275–284. doi:10.1016/j.resinv.2020.01.003
   PubMed Web of Science ®Google Scholar
• LinL, HanQ, XiongY, et al. Krüpple-like-factor 4 attenuates lung fibrosis via inhibiting epithelial-mesenchymal transition. Sci Rep. 2017;7:15847. doi:10.1038/s41598-017-14602-7.29158503
   PubMed Web of Science ®Google Scholar
• HanQ, LinL, ZhaoB, et al. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2018;500:839–845. doi:10.1016/j.bbrc.2018.04.14829704504
   PubMed Web of Science ®Google Scholar
• GoldmannT, ZisselG, WatzH, et al. Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis. Respir Res. 2018;19:138. doi:10.1186/s12931-018-0841-9.30041633
   PubMed Web of Science ®Google Scholar
• ChaudharyNI, RothGJ, HilbergF, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976–985. doi:10.1183/09031936.0015210617301095
   PubMed Web of Science ®Google Scholar
• RaghuG, Remy-JardinM, MyersJL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68. doi:10.1164/rccm.201807-1255ST30168753
   PubMed Web of Science ®Google Scholar
• NicholsonAG, FulfordLG, ColbyTV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;166:173–177. doi:10.1164/rccm.2109039.12119229
   PubMed Web of Science ®Google Scholar
• NakataniY, NishidaK, SakabeM, et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:582–588. doi:10.1016/j.jacc.2012.11.014.23273396
   PubMed Web of Science ®Google Scholar
• MoriH, TanakaH, KawadaK, et al. Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis. Jpn J Pharmacol. 1995;67:279–289. doi:10.1254/jjp.67.2797544418
   PubMedGoogle Scholar
• AokiY, KojoY, YamadaS, et al. Respirable dry powder formulation of bleomycin for developing a pulmonary fibrosis animal model. J Pharm Sci. 2012;101:2074–2081. doi:10.1002/jps.23102.22388976
   PubMed Web of Science ®Google Scholar
• MoriH, KawadaK, ZhangP, UesugiY, SakamotoO, KodaA. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int Arch Allergy Appl Immunol. 1991;95:195–201. doi:10.1159/0002354291718909
   PubMedGoogle Scholar
• SinghA, GreningerP, RhodesD, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489–500. doi:10.1016/j.ccr.2009.03.022.19477428
   PubMed Web of Science ®Google Scholar
• NambaT, TanakaK-I, ItoY, et al. Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis. Cell Death Differ. 2010;17:1882–1895. doi:10.1038/cdd.2010.6420489727
   PubMed Web of Science ®Google Scholar
• KyungSY, KimDY, YoonJY, et al. Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacol Toxicol. 2018;19:13. doi:10.1186/s40360-018-0204-7.29609658
   PubMed Web of Science ®Google Scholar
• LiaoK, YongCW, HuaK, et al. SB431542 inhibited cigarette smoke extract induced invasiveness of A549 cells via the TGF-β1/Smad2/MMP3 pathway. Oncol Lett. 2018;15:9681–9686. doi:10.3892/ol.2018.855629963124
   PubMed Web of Science ®Google Scholar
• PattarayanD, SivananthamA, KrishnaswamiV. Tannic acid attenuates TGF-β1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-β signaling in lung epithelial cells. J Cell Physiol. 2018;233:2513–2525. doi:10.1002/jcp.2612728771711
   PubMed Web of Science ®Google Scholar
• ZhangC, ZhuX, HuaY, et al. YY1 mediates TGF-β1-induced EMT and pro-fibrogenesis in alveolar epithelial cells. Respir Res. 2019;20:249. doi:10.1186/s12931-019-1223-7.31703732
   PubMed Web of Science ®Google Scholar